Author:
Przystal Justyna Magdalena,Hajji Nabil,Khozoie Combiz,Renziehausen Alexander,Zeng Qingyu,Abaitua Fernando,Hajitou Amin,Suwan Keittisak,Want Elizabeth,Bomalaski John,Szlosarek Peter,O’Neill Kevin,Crook Tim,Syed Nelofer
Funder
Brain Tumour Research Campaign UK Brain Tumour Research UK
Brain Tumour Research Campaign Brain Tumour Research
Barrow Neurological Institute
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference32 articles.
1. Thomas, R. P., Recht, L. & Nagpal, S. Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin. Pharmacol. 5, 1–9 (2013).
2. Moren, L. et al. Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM. BMC Cancer 18, 167 (2018).
3. Syed, N. et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis. 4, e458 (2013).
4. Gong, H., Zolzer, F., von Recklinghausen, G., Havers, W. & Schweigerer, L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 14, 826–829 (2000).
5. Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S. & Clark, M. A. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62, 5443–5450 (2002).
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献